Bills · HR 6214
IN COMMITTEE· 119TH CONGRESS
House BillHR 6214Health
Kidney Care Access Protection Act
INTRO NOV 20· LAST ACTION NOV 20
READING
11MIN
COSPONSORS
16BIPARTISAN
READER REACTIONS0 TOTAL
NO VOTES YET · BE THE FIRST
- Introduced only
LEGISLATIVE PROGRESS
STEP 2 / 8Introduced
In Committee
Reported
Passed House
Passed Senate
Conference
To President
Became Law
WHAT THE BILL DOES
AI-writtenThis bill matters because it addresses how quickly and consistently people with severe kidney disease can access cutting-edge treatments. Currently, providers might be hesitant to adopt new, potentially expensive, but effective drugs or devices if Medicare payments don't adequately cover their costs for a long enough time. By extending temporary payments and creating a permanent add-on payment for new therapies, the bill aims to remove financial barriers for providers.
If this bill becomes law, patients with ESRD could have earlier and more reliable access to the latest medical innovations, which could improve their health outcomes and quality of life. If it doesn't pass, the current payment system might continue to slow the adoption of new technologies, potentially leaving patients without access to advanced care that could benefit them. This bill is relevant to the ongoing challenge of balancing healthcare innovation with the financial sustainability of public health programs like Medicare.
KEY PROVISIONS
5AI-extractedPROVISION 01
Extends the temporary Medicare add-on payment period for new kidney dialysis drugs and biological products (TDAPA) from 2 to at least 3 years.
This ensures that providers are reimbursed for new, often expensive, innovative drugs for a longer period, encouraging their use.
PROVISION 02
Establishes a permanent add-on payment for certain innovative kidney dialysis drugs and biological products after their temporary TDAPA period expires.
This creates long-term financial stability for providers offering these therapies, further incentivizing innovation and sustained patient access.
PROVISION 03
Extends the temporary Medicare add-on payment period for new and innovative kidney dialysis equipment and supplies (TPNIES) from 2 to at least 3 years.
Similar to drugs, this encourages the adoption of new medical devices and technologies in kidney care by extending reimbursement support.
PROVISION 04
Makes devices designated as 'breakthrough devices' by the FDA automatically eligible for the temporary add-on payment for new equipment and supplies (TPNIES).
This streamlines the process for highly innovative and rapidly developed devices to receive Medicare coverage and payment.
PROVISION 05
Clarifies that certain new drugs and biological products approved after December 31, 2025, used to treat other health conditions common in ESRD patients (e.g., heart disease, diabetes) are not part of the bundled dialysis payment, provided they don't replace existing bundled drugs.
This ensures separate payment for important new therapies addressing co-existing conditions, potentially broadening treatment options for ESRD patients.
SPONSORSHIP
1 + 16
R· West Virginia
YRS IN OFFICE
7
BILLS LED
30
COSPONSOR BREAKDOWNBIPARTISAN · 87%
DEM 7 REP 9 IND 0
ACTION TIMELINE
2 EVENTSNOV 20
Introduced in House
NOV 20
Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
BILL INFO
TypeHouse Bill
NumberHR 6214
Congress119th
StatusIn Committee
IntroducedNov 20, 2025
Last actionNov 20, 2025
READER REACTIONS
OVERALL SENTIMENT
No reactions yet. Be the first to weigh in.
Discussion
Loading comments...
IN COMMITTEE· 119TH CONGRESS · WAYS AND MEANS COMMITTEE · INTRODUCED NOV 20, 2025
House BillHR 6214Health
Kidney Care Access Protection Act
INTRODUCED NOV 20, 2025· LAST ACTION NOV 20, 2025
PASSAGE CHANCES
—%
READING
11 min
COSPONSORS
16
COMPLEXITY
Moderate
